Physician profile
Gregory Richter
NPI 1518967181
$11,514.73
in general payments reported to CMS, 2019-2025
40 companies · $1,807 in 2025
The $1,807 reported for 2025 was more than what 94% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,046 · 2020: $1,261 · 2021: $1,438 · 2022: $1,947 · 2023: $1,986 · 2024: $2,030 · 2025: $1,807.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,823.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,823.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,004.94 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Abbvie INC. | $1,591.01 | 2021-2025 | |
| Lilly USA, LLC | $1,267.58 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $799.13 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Pfizer INC. | $756.24 | 2019-2025 | |
| Amgen INC. | $583.02 | 2019-2025 | Evenity, Prolia, Otezla |
| Novo Nordisk INC | $582.10 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Amarin Pharma, INC. | $460.76 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $406.00 | 2019-2025 | Capvaxive, Gardasil 9 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $354.08 | 2019-2025 | Jardiance, Tradjenta, Synjardy |
| Sanofi-Aventis U.S. LLC | $340.83 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $333.87 | 2019-2025 | Xarelto, Spravato |
| Mylan Specialty L.P. | $262.17 | 2021-2024 | Yupelri |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $160.67 | 2019-2025 | Xifaxan |
| Novartis Pharmaceuticals Corporation | $143.77 | 2019-2023 |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $143.09 | 2022-2024 | Quviviq |
| Allergan, INC. | $125.97 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $123.90 | 2019-2021 | |
| Phathom Pharmaceuticals, INC. | $101.78 | 2024-2025 | Voquezna |
| Kowa Pharmaceuticals America, INC. | $98.84 | 2019-2021 | |
| Abbott Laboratories | $92.35 | 2021-2025 | Freestyle Libre 3 |
| E.R. Squibb & Sons, L.L.C. | $83.23 | 2023-2024 | Eliquis, Camzyos |
| Exact Sciences Corporation | $78.65 | 2023-2025 | Cologuard Collection Kit |
| Boston Scientific Corporation | $78.54 | 2024-2025 | Watchman Flx, Watchman Access System |
| Corcept Therapeutics | $66.49 | 2025 | Korlym |
| Otsuka America Pharmaceutical, INC. | $64.24 | 2023-2024 | Rexulti, Nuedexta |
| Astellas Pharma US INC | $62.78 | 2019-2025 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $55.74 | 2024-2025 | |
| Eisai INC. | $47.04 | 2021 | |
| Nevro Corp. | $46.33 | 2022 | |
| Genentech USA, INC. | $36.95 | 2019-2022 | |
| Lundbeck LLC | $30.95 | 2024 | Vyepti |
| Esperion Therapeutics, INC. | $26.04 | 2021 | |
| Almatica Pharma LLC | $20.74 | 2022 | |
| Optos, INC. | $17.27 | 2020 | |
| Ibsa Pharma INC. | $15.27 | 2021 | |
| Tactile Systems Technology INC | $14.30 | 2022 | |
| Currax Pharmaceuticals LLC | $14.29 | 2023 | Contrave |
| Sanofi Pasteur INC. | $12.55 | 2020 | |
| Ultragenyx Pharmaceutical INC. | $11.23 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Richter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.